1. CALQUENCE® RCP

2. www.riziv.fgov.be

3. https://cns.public.lu/fr/professionnels-sante/medicaments/liste-positive.html

4. Barf T, et al. J Pharmacol Exp Ther. 2017;363(2):240-252. 2.

5. Sharman JP, et al. Acalabrutinib ± Obinutuzumab vs Obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia:
ELEVATE-TN 4-year follow-up. Presentation presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 4-8, 2021 (Virtual meeting).

6. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow-up of ELEVATE-TN. [Poster] Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; June 3-7, 2022; Chicago, Illinois.

7. Sharman JP et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022; doi: 10.1038/s41375-021-01485-x.

8. Data on File, REF-113076. AstraZeneca Pharmaceuticals LP.

9. Byrd JC, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol. 2021; published online on Jul 26: DOI https://doi.org/101200/JCO.21.01210.

10. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated
chronic lymphocytic leukemia. Presentation presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-31, 2020 (Virtual Meeting). 

11. Ghia P, et al. Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic LymphocyticLeukemia: Final ASCEND Trial Results. Hemasphere. 2022 Nov 14;6(12): 1-10.

12. Jurczak W et al. Three-Year Follow-Up of the ASCEND Trial: Acalabrutinib vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Presentation at: ASH; December 11-14, 2021.